Lemaitre Vascular Inc. (LMAT) is an internationally recognized company in the development, manufacture, and distribution of medical devices used in the treatment of peripheral vascular disease. Founded in 1983 by surgeon George D. LeMaitre, the company's constant commitment to innovation and improvement has positioned it as a global leader in vascular surgery.
Lemaitre Vascular Inc. is publicly traded on the NASDAQ Global Market under the symbol LMAT. It is based in Burlington, Massachusetts, USA, with additional offices and distribution networks across North America, Europe, Asia, and Australia. This allows the company to service physicians, hospitals, and medical facilities throughout the world.
The company offers over 20 different types of medical devices, including the patented AlboGraft® Polyester Vascular Graft which is widely recognized for its superior resistance to aneurysm formation. Other innovative products range from embolectomy catheters, vascular grafts, valvulotomes, stent grafts, to carotid shunts and remote endarterectomy devices. The company also recently introduced the XenoSure® Biologic Patch to reduce bleeding in vascular surgery procedures.
Lemaitre Vascular Inc. is committed to the highest manufacturing and quality control standards, with manufacturing facilities in Massachusetts, California, Canada, and Italy that adhere strictly to the regulations of the U.S. Food & Drug Administration (FDA) and the European CE Mark.
Moreover, the company places a strong emphasis on maintaining close ties with the medical community. Through continuous dialogue with physicians and clinicians, Lemaitre Vascular Inc. can assess and respond swiftly to unmet clinical needs, driving the development and improvement of their products.
Despite its success, Lemaitre Vascular remains committed to the same passion and vision for innovation that it had as a small surgical start-up. This speaks volumes as to why Lemaitre Vascular Inc. is revered not only for its groundbreaking medical devices but also for its dedication in improving vascular care worldwide. With a continued emphasis on product refinement and development, the company is dedicated to fulfilling its mission of providing best-in-class vascular devices to surgeons and improving patient care.
In summary, Lemaitre Vascular Inc. exemplifies a successful medical device company that integrates continuous innovation, superior quality, and close interaction with the medical community, leading to improved treatment of peripheral vascular diseases and better outcomes for patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Bank of America Corp DE recently acquired 140,936 shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the second quarter, valued at approximately $13.5 million. This purchase makes Bank of America a 0.62% owner of the medical instruments supplier, whose stock is largely held by institutional investors at 84.64%. Despite missing recent earnings estimates, LeMaitre Vascular announced a quarterly dividend of $0.25 per share, and analysts currently hold a "Hold" consensus rating on the stock with an average price target of $110.60.
This article provides an AI-driven analysis of Lemaitre Vascular Inc. (LMAT), highlighting weak near-term sentiment and elevated downside risk. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk profiles. The analysis also includes multi-timeframe signal data for near-term, mid-term, and long-term perspectives.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received an average "Hold" rating from nine brokerages, with an average 12-month price target of $110.60. The company's shares opened at $78.87, near its 52-week low, and its recent quarterly earnings of $0.74 EPS on $70.38 million in revenue missed analyst expectations, despite a 9.6% year-over-year revenue growth. Several analysts have recently downgraded their ratings or cut price targets for LMAT.
Legal & General Group Plc has acquired a new stake in LeMaitre Vascular, Inc. worth approximately $4.84 million, purchasing 50,434 shares. This investment gives Legal & General Group Plc a 0.22% ownership in the medical instruments supplier, while institutional investors collectively hold 84.64% of the company's stock. LeMaitre Vascular recently reported Q2 EPS of $0.74, missing consensus estimates, but analysts anticipate full-year EPS of $2.89, with the stock currently trading near its 12-month low.
Corient Private Wealth LP has acquired a new stake of 25,619 shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) valued at approximately $2.46 million during the second quarter. This purchase contributes to the 84.64% institutional ownership of the company. Despite LeMaitre Vascular missing its Q2 earnings and revenue estimates, the company's revenue increased by 9.6% year-over-year, and it declared a quarterly dividend of $0.25 per share.
Man Group plc recently acquired 29,417 shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) for approximately $2.82 million, establishing a 0.13% stake in the medical instruments supplier. The stock currently has a "Hold" consensus rating from analysts with an average target price of $110.60, despite the company missing its latest quarterly earnings and revenue expectations. LeMaitre Vascular also declared a quarterly dividend of $0.25 per share, representing a 1.2% yield.
Riverwater Partners' Small Cap Strategy underperformed the Russell 2000 in Q2 2026 due to a speculative rally favoring high-beta stocks, which negatively impacted their quality-focused approach and healthcare holdings like LeMaitre Vascular (LMAT). Despite LMAT's 12% decline in the quarter, Riverwater Partners maintains that the company's fundamental strengths, including niche leadership and consistent execution, remain intact, viewing the weakness as sentiment-driven. While acknowledging LMAT's potential, the firm is also exploring AI stocks with greater upside and less downside risk.
Bank of New York Mellon Corp has acquired a new stake of $16.55 million in LeMaitre Vascular, Inc., purchasing 172,458 shares. This investment means institutional investors now collectively own 84.64% of LMAT, despite the company recently missing quarterly earnings estimates and receiving a mixed "Hold" consensus rating from analysts. LeMaitre Vascular also declared a quarterly dividend of $0.25 per share, representing a 1.2% yield.
Grandeur Peak Global Advisors LLC significantly increased its stake in LeMaitre Vascular, Inc. (LMAT) by 63.1% in the second quarter, making it their 7th largest position. Despite this increased institutional interest, LeMaitre Vascular's recent quarterly results missed analyst expectations, and the company currently holds a consensus "Hold" rating with an average price target of $110.60. The medical instruments supplier also declared a quarterly dividend of $0.25 per share.